Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 310-318 , July 2004

Vascular biology in uremia: insights into novel mechanisms of vascular injury

  • Ziyad Al Aly

      Affiliations

    • Division of Nephrology, St Louis University, USA
    • Corresponding Author InformationAddress correspondence to Ziyad Al Aly, MD, St Louis University, Division of Nephrology, 3635 Vista Ave FDT 9N, St Louis, MO 63110 USA
    • ,
  • John C Edwards

      Affiliations

    • Division of Nephrology, St Louis University, USA
    • St Louis VA Medical Center, St Louis, MO, USA

References 

  1. USRDS (the United States Renal Data System). Am J Kidney Dis. 2003;42(suppl 5):1–230
  2. Shoji T, Emoto M, Tabata T, et al.  Advanced atherosclerosis in predialysis patients with chronic renal failure. Kidney Int. 2002;61:2187–2192
  3. Ishimura E, Shoji T, Emoto M, et al.  Renal insufficiency accelerates atherosclerosis in patients with type 2 diabetes mellitus. Am J Kidney Dis. 2001;38(suppl 1):S186–S190
  4. Kimmel PL, Phillips TM, Simmens SJ, et al.  Immunologic function and survival in hemodialysis patients. Kidney Int. 1998;54:236–244
  5. Pecoits-Filho R, Barany P, Lindholm B, et al.  Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant. 2002;17:1684–1688
  6. Yeun JY, Levine RA, Mantadilok V, et al.  C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis. 2000;35:469–476
  7. Yudkin JS, Kumari M, Humphries SE, et al.  Inflammation, obesity, stress and coronary heart disease (Is interleukin-6 the link?). Atherosclerosis. 2000;148:209–214
  8. Huber SA, Sakkinen P, Conze D, et al.  Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 1999;19:2364–2367
  9. Pigott R, Dillon LP, Hemingway IH, et al.  Soluble forms of E-selectin, ICAM-1 and VCAM-1 are present in the supernatants of cytokine activated cultured endothelial cells. Biochem Biophys Res Commun. 1992;187:584–589
  10. Wassmann S, Stumpf M, Strehlow K, et al.  Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004;94:534–541
  11. Ridker PM, Rifai N, Stampfer MJ, et al.  Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767–1772
  12. Kato A, Odamaki M, Takita T, et al.  Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 2002;61:1143–1152
  13. Stenvinkel P, Barany P, Heimburger O, et al.  Mortality, malnutrition, and atherosclerosis in ESRD (What is the role of interleukin-6?). Kidney Int. 2002;80(suppl):103–108
  14. Stenvinkel P, Heimburger O, Jogestrand T. Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients (Association with Chlamydia pneumoniae seropositivity). Am J Kidney Dis. 2002;39:274–282
  15. Netea MG, Selzman CH, Kullberg BJ, et al.  Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells. Eur J Immunol. 2000;30:541–549
  16. Tsirpanlis G, Chatzipanagiotou S, Ioannidis A, et al.  The effect of viable Chlamydia pneumoniae on serum cytokines and adhesion molecules in hemodialysis patients. Kidney Int. 2003;84(suppl):S72–S75
  17. Zoccali C, Mallamaci F, Tripepi G, et al.  Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). Kidney Int. 2003;64:579–584
  18. Mallat Z, Besnard S, Duriez M, et al.  Protective role of interleukin-10 in atherosclerosis. Circ Res. 1999;85:E17–E24
  19. Von Der Thusen JH, Kuiper J, Fekkes ML, et al.  Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J. 2001;15:2730–2732
  20. Perianayagam MC, Jaber BL, Guo D, et al.  Defective interleukin-10 synthesis by peripheral blood mononuclear cells among hemodialysis patients. Blood Purif. 2002;20:543–550
  21. Girndt M, Kaul H, Sester U, et al.  Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events. Kidney Int. 2002;62:949–955
  22. Annuk M, Zilmer M, Lind L, et al.  Oxidative stress and endothelial function in chronic renal failure. J Am Soc Nephrol. 2001;12:2747–2752
  23. Fillit H, Elion E, Sullivan J, et al.  Thiobarbituric acid reactive material in uremic blood. Nephron. 1981;29:40–43
  24. Taccone-Gallucci M, Lubrano R, Del Principe D, et al.  Platelet lipid peroxidation in haemodialysis patients (Effects of vitamin E supplementation). Nephrol Dial Transplant. 1989;4:975–978
  25. Annuk M, Fellstrom B, Akerblom O, et al.  Oxidative stress markers in pre-uremic patients. Clin Nephrol. 2001;56:308–314
  26. Holvoet P, Collen D. Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis. Atherosclerosis. 1998;137(suppl):S33–38
  27. Dawnay A, Millar DJ. The pathogenesis and consequences of AGE formation in uraemia and its treatment. Cell Mol Biol (Noisy-le-grand). 1998;44:1081–1094
  28. Nguyen-Khoa T, Massy ZA, De Bandt JP, et al.  Oxidative stress and haemodialysis (Role of inflammation and duration of dialysis treatment). Nephrol Dial Transplant. 2001;16:335–340
  29. Wang HH, Hung TM, Wei J, et al.  Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoE-knockout mice. Cardiovasc Res. 2004;61:169–176
  30. Fleck C, Schweitzer F, Karge E, et al.  Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin Chim Acta. 2003;336:1–12
  31. Cooke JP. Does ADMA cause endothelial dysfunction?. Arterioscler Thromb Vasc Biol. 2000;20:2032–2037
  32. Zoccali C, Mallamaci F, Tripepi G. Novel cardiovascular risk factors in end-stage renal disease. J Am Soc Nephrol. 2004;15(suppl 1):S77–S80
  33. Boger RH, Zoccali C. ADMA (A novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease). Atheroscler. 2003;4(suppl):23–28
  34. Zoccali C, Mallamaci F, Maas R, et al.  Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339–345
  35. Zoccali C, Benedetto FA, Maas R, et al.  Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol. 2002;13:490–496
  36. Zoccali C, Bode-Boger S, Mallamaci F, et al.  Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease (A prospective study). Lancet. 2001;358:2113–2117
  37. Podrez EA, Abu-Soud HM, Hazen SL. Myeloperoxidase-generated oxidants and atherosclerosis. Free Radic Biol Med. 2000;28:1717–1725
  38. Hazen SL, Heinecke JW. 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest. 1997;99:2075–2081
  39. Podrez EA, Schmitt D, Hoff HF, et al.  Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547–1560
  40. Schmitt D, Shen Z, Zhang R, et al.  Leukocytes utilize myeloperoxidase-generated nitrating intermediates as physiological catalysts for the generation of biologically active oxidized lipids and sterols in serum. Biochemistry. 1999;38:16904–16915
  41. Zhang R, Brennan ML, Shen Z, et al.  Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation. J Biol Chem. 2002;277:46116–46122
  42. Abu-Soud HM, Hazen SL. Nitric oxide is a physiological substrate for mammalian peroxidases. J Biol Chem. 2000;275:37524–37532
  43. Himmelfarb J, McMenamin ME, Loseto G, et al.  Myeloperoxidase-catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med. 2001;31:1163–1169
  44. Kutter D, Devaquet P, Vanderstocken G, et al.  Consequences of total and subtotal myeloperoxidase deficiency (Risk or benefit?). Acta Haematol. 2000;104:10–15
  45. Zhang R, Brennan ML, Fu X, et al.  Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136–2142
  46. Pecoits-Filho R, Stenvinkel P, Marchlewska A, et al.  A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients. Kidney Int. 2003;84(suppl):S172–S176
  47. Nikpoor B, Turecki G, Fournier C, et al.  A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in French-Canadians. Am Heart J. 2001;142:336–339
  48. Annuk M, Zilmer M, Fellstrom B. Endothelium-dependent vasodilation and oxidative stress in chronic renal failure (impact on cardiovascular disease). Kidney Int. 2003;84(suppl):S50–S53
  49. Bolto CH, Downs LG, Victory JG, et al.  Endothelial dysfunction in chronic renal failure (roles of lipoprotein oxidation and proinflammatory cytokines). Nephrol Dial Transplant. 2001;16:1189–1197
  50. Goodman WG, Goldin J, Kuizon BD, et al.  Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478–1483
  51. Salgueira M, Del Toro N, Moreno-Alba R, et al.  Vascular calcification in the uremic patient (A cardiovascular risk?). Kidney Int. 2003;85(suppl):119–121
  52. Reslerova M, Moe SM. Vascular calcification in dialysis patients (Pathogenesis and consequences). Am J Kidney Dis. 2003;41(suppl 1):S96–S99
  53. Blacher J, Guerin AP, Pannier B, et al.  Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension. 2001;38:938–942
  54. London GM, Guerin AP, Marchais SJ, et al.  Arterial media calcification in end-stage renal disease (Impact on all-cause and cardiovascular mortality). Nephrol Dial Transplant. 2003;18:1731–1740
  55. Virchow R. Cellular Pathology (As Based Upon Physiological and Pathological Histology). New York, NY: Dover; 1971;
  56. Tintut Y, Demer LL. Recent advances in multifactorial regulation of vascular calcification. Curr Opin Lipidol. 2001;12:555–560
  57. Demer LL, Tintut Y. Mineral exploration: Search for the mechanism of vascular calcification and beyond: the 2003 Jeffrey M. Hoeg Award lecture. Arterioscler Thromb Vasc Biol. 2003;23:1739–1743
  58. Towler DA, Bidder M, Latifi T, et al.  Diet-induced diabetes activates an osteogenic gene regulatory program in the aortas of low density lipoprotein receptor-deficient mice. J Biol Chem. 1998;273:30427–30434
  59. Engelse MA, Neele JM, Bronckers AL, et al.  Vascular calcification (Expression patterns of the osteoblast-specific gene core binding factor alpha-1 and the protective factor matrix Gla protein in human atherogenesis). Cardiovasc Res. 2001;52:281–289
  60. Bostrom K, Watson KE, Horn S, et al.  Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800–1809
  61. Parhami F, Bostrom K, Watson K, et al.  Role of molecular regulation in vascular calcification. J Atheroscler Thromb. 1996;3:90–94
  62. Giachelli CM. Ectopic calcification (gathering hard facts about soft tissue mineralization). Am J Pathol. 1999;154:671–675
  63. Luo G, Ducy P, McKee MD, et al.  Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78–81
  64. Kuro-o M, Matsumura Y, Aizawa H, et al.  Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45–51
  65. Bucay N, Sarosi I, Dunstan CR, et al.  Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–1268
  66. Tintut Y, Patel J, Parhami F, et al.  Tumor necrosis factor-alpha promotes in vitro calcification of vascular cells via the cAMP pathway. Circulation. 2000;102:2636–2642
  67. Tintut Y, Patel J, Territo M, et al.  Monocyte/macrophage regulation of vascular calcification in vitro. Circulation. 2002;105:650–655
  68. Ketteler M, Vermeer C, Wanner C, et al.  Novel insights into uremic vascular calcification (Role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin). Blood Purif. 2002;20:473–476
  69. Price PA, Williamson MK. Primary structure of bovine matrix Gla protein, a new vitamin K-dependent bone protein. J Biol Chem. 1985;260:14971–14975
  70. Price PA, Faus SA, Williamson MK. Warfarin-induced artery calcification is accelerated by growth and vitamin D. Arterioscler Thromb Vasc Biol. 2000;20:317–327
  71. Farzaneh-Far A, Davies JD, Braam LA, et al.  A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem. 2001;276:32466–32473
  72. Herrmann SM, Whatling C, Brand E, et al.  Polymorphisms of the human matrix Gla protein (MGP) gene, vascular calcification, and myocardial infarction. Arterioscler Thromb Vasc Biol. 2000;20:2386–2393
  73. Ketteler M, Bongartz P, Westenfeld R, et al.  Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis (A cross-sectional study). Lancet. 2003;361:827–833
  74. Ketteler M, Wanner C, Metzger T, et al.  Deficiencies of calcium-regulatory proteins in dialysis patients (A novel concept of cardiovascular calcification in uremia). Kidney Int. 2003;84(suppl):S84–S87
  75. Schafer C, Heiss A, Schwarz A, et al.  The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357–366
  76. Lebreton JP, Joisel F, Raoult JP, et al.  Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process (Evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant). J Clin Invest. 1979;64:1118–1129
  77. Binkert C, Demetriou M, Sukhu B, et al.  Regulation of osteogenesis by fetuin. J Biol Chem. 1999;274:28514–28520
  78. Mathews ST, Singh GP, Ranalletta M, et al.  Improved insulin sensitivity and resistance to weight gain in mice null for the Ahsg gene. Diabetes. 2002;51:2450–2458
  79. Jahnen-Dechent W, Schinke T, Trindl A, et al.  Cloning and targeted deletion of the mouse fetuin gene. J Biol Chem. 1997;272:31496–31503
  80. Price PA, Williamson MK, Nguyen TM, et al.  Serum levels of the fetuin-mineral complex correlate with artery calcification in the rat. J Biol Chem. 2004;279:1594–1600
  81. Proudfoot D, Skepper JN, Shanahan CM, et al.  Calcification of human vascular cells in vitro is correlated with high levels of matrix Gla protein and low levels of osteopontin expression. Arterioscler Thromb Vasc Biol. 1998;18:379–388
  82. Canfield AE, Farrington C, Dziobon MD, et al.  The involvement of matrix glycoproteins in vascular calcification and fibrosis (An immunohistochemical study). J Pathol. 2002;196:228–234
  83. Jono S, McKee MD, Murry CE, et al.  Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10–E17
  84. Giachelli CM, Jono S, Shioi A, et al.  Vascular calcification and inorganic phosphate. Am J Kidney Dis. 2001;38(suppl 1):S34–S37
  85. Wolf G, Chen S, Han DC, et al.  Leptin and renal disease. Am J Kidney Dis. 2002;39:1–11
  86. Parhami F, Tintut Y, Ballard A, et al.  Leptin enhances the calcification of vascular cells (Artery wall as a target of leptin). Circ Res. 2001;88:954–960

PII: S1548-5595(04)00075-8

doi: 10.1053/j.arrt.2004.04.006

Advances in Chronic Kidney Disease
Volume 11, Issue 3 , Pages 310-318 , July 2004

Article Tools